#Canada #Toronto #AI Technology #Perimeter Medical #Claire OCT

Perimeter Medical Imaging AI Announces Financial Results for Q2 2026

Perimeter Medical Imaging AI, Inc., a leading company in the medical technology sector, has released its preliminary financial results for the second quarter of 2026, highlighting significant milestones in its operational and commercial strategies. The results reflect a strong performance driven by the introduction of its revolutionary AI-enabled imaging system, Claire™.

Strong Commercial Momentum

During the second quarter, Perimeter experienced a remarkable growth in recurring revenue, primarily derived from the sales of consumables related to its legacy S-Series OCT systems, with a sequential quarterly increase of 31%. CEO Adrian Mendes noted that the transition from their older S-Series device to the advanced Claire OCT system is progressing smoothly. This transition was underscored by the successful unveiling of Claire at the American Society of Breast Surgeons Annual Meeting held in April 2026. This event not only marked the official launch of Claire but also set the stage for its initial placements at top-tier hospitals.

By May 2026, Perimeter successfully completed its first two commercial placements of the Claire device, showcasing its capabilities in breast-conserving surgeries. Additionally, the company received a $148,000 contribution from the INOVAIT Pilot Fund to enhance the infrastructure for the Claire system, demonstrating ongoing support from key health innovation initiatives.

In a landmark achievement, the first U.S. health system, Intermountain Health, has integrated Claire into its operations for real-time margin assessment during breast surgeries, solidifying the device's position as a vital tool in the operating room.

Financial Overview

In terms of financial performance, Perimeter reported revenues of approximately $503,000 for Q2 2026, largely stable compared to $506,000 generated in Q1 2025. This revenue mainly stems from the recurring income associated with the S-Series consumables and lease agreements, alongside maintenance services. By comparison, this figure marked an increase of 31% from approximately $385,000 earned in the previous quarter.

Operating expenses were reported at roughly $3.1 million, reflecting a significant decrease of 28% from $4.3 million in the same timeframe last year. The net loss for the quarter stood around $2.6 million, offering an improvement of 33% relative to approximately $3.9 million incurred in Q2 2025. This brings the per-share loss down to $0.02, showcasing a strong advancement in operational efficiency.

As of June 30, 2026, Perimeter's cash holdings amounted to $6.4 million, supported by strategic fundraising initiatives finalized earlier in the year. A notable achievement includes the closure of their non-brokered private placement, resulting in a substantial influx of capital amounting to C$6,040,000.

Looking Forward

Following the recent financial results, Perimeter plans to host a conference call to discuss further insights into the second quarter achievements and strategic directions moving forward. Mendes expressed optimism in the company’s trajectory, stating that the strong commercial momentum positions Perimeter well for future growth and innovation in breast cancer surgery.

In summary, Perimeter Medical Imaging AI continues to demonstrate resilience and adaptability in the medical technology landscape. The transition to the Claire OCT system, combined with promising financial results, signifies a solid foundation as the company advances its mission to improve healthcare outcomes through innovative imaging technology.